To date, assessment of cancer therapy-related cardiotoxicity has relied largely on serum biomarker measures (TNI, BNP, NT-proBNP, etc.)and cardiac imaging tests (echocardiography, CMR, etc.)(17, 38, 39). This evidence concerns the gene NPPB and cancer.